The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Feldene     (8E)-8-[hydroxy-(pyridin-2...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Feldene


Psychiatry related information on Feldene

  • However, inhibition of circulating PG by piroxicam did not block the reductions in appetite, crossover, and rears induced by rIL-1 alpha; it restored normal drinking behavior and only partially restored body weight [5].
  • Subsequent treatment with either intramuscular or oral piroxicam further improved these symptoms and most patients recovered their normal physical activity within a week [6].
  • CONCLUSIONS: These results suggest that piroxicam is as effective as diclofenac sodium in preventing inflammation after cataract surgery with IOL implantation, and its better tolerance and safety can provide higher patient compliance [7].

High impact information on Feldene


Chemical compound and disease context of Feldene


Biological context of Feldene


Anatomical context of Feldene

  • In contrast, none of the doses of piroxicam alone decreased tumor multiplicity in the proximal portion of the intestine (duodenum) [23].
  • Piroxicam at 12, 25, and 50 ppm in the diet caused dose-dependent decreases in the number of tumors in the middle and distal portions of the small intestine [23].
  • In addition, we evaluated the ability of piroxicam, a potent COX inhibitor, to prevent postinitiation events of NMBA-induced tumorigenesis in the rat esophagus [24].
  • Furthermore, piroxicam significantly decreased the amount of L-selectin shed by cytokine-treated neutrophils, whereas it did not exert this effect on PMA- or A23187-treated neutrophils [25].
  • Moreover, in chemokine-treated T lymphocytes, the expression of activation epitopes on beta 1 integrins was also diminished by piroxicam [25].

Associations of Feldene with other chemical compounds


Gene context of Feldene


Analytical, diagnostic and therapeutic context of Feldene


  1. Fatal pemphigus vulgaris in a patient taking piroxicam. Martin, R.L., McSweeney, G.W., Schneider, J. N. Engl. J. Med. (1983) [Pubmed]
  2. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. Reports to a specialty-based system for spontaneous reporting of adverse reactions to drugs. Stern, R.S., Bigby, M. JAMA (1984) [Pubmed]
  3. Severe cholestatic jaundice associated with piroxicam. Hepps, K.S., Maliha, G.M., Estrada, R., Goodgame, R.W. Gastroenterology (1991) [Pubmed]
  4. Piroxicam-induced renal failure and hyperkalemia. Frais, M.A., Burgess, E.D., Mitchell, L.B. Ann. Intern. Med. (1983) [Pubmed]
  5. Role of prostaglandins in the behavioral changes induced by murine interleukin 1 alpha in the rat. Otterness, I.G., Golden, H.W., Seymour, P.A., Eskra, J.D., Daumy, G.O. Cytokine (1991) [Pubmed]
  6. Intramuscular piroxicam, a new dosage form, in the treatment of acute musculoskeletal disorders. Wiseman, R.L., Kilgour, M. J. Int. Med. Res. (1985) [Pubmed]
  7. Effectiveness and tolerance of piroxicam 0.5% and diclofenac sodium 0.1% in controlling inflammation after cataract surgery. Scuderi, B., Driussi, G.B., Chizzolini, M., Salvetat, M.L., Beltrame, G. European journal of ophthalmology. (2003) [Pubmed]
  8. Administration of nonsteroidal anti-inflammatory agents in patients with rheumatoid arthritis. Effects on indexes of cellular immune status and serum rheumatoid factor levels. Goodwin, J.S., Ceuppens, J.L., Rodriguez, M.A. JAMA (1983) [Pubmed]
  9. Phorbol ester-stimulated secretion in chicken ileum: role of arachidonic acid metabolism. Musch, M.W., Nahkla, A.M., Chang, E.B. Gastroenterology (1990) [Pubmed]
  10. Influence of atrial natriuretic peptide on mammalian large intestine. Moriarty, K.J., Higgs, N.B., Lees, M., Tonge, A., Wardle, T.D., Warhurst, G. Gastroenterology (1990) [Pubmed]
  11. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Pamukcu, R., Hanauer, S.B., Chang, E.B. Gastroenterology (1988) [Pubmed]
  12. Piroxicam and pancreatitis. Haye, O.L. Ann. Intern. Med. (1986) [Pubmed]
  13. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Halberg, R.B., Katzung, D.S., Hoff, P.D., Moser, A.R., Cole, C.E., Lubet, R.A., Donehower, L.A., Jacoby, R.F., Dove, W.F. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  14. Synergy between phorbol esters, 1-oleyl-2-acetylglycerol, urushiol, and calcium ionophore in eliciting aggregation of marine sponge cells. Weissmann, G., Azaroff, L., Davidson, S., Dunham, P. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  15. Interleukin-1 induces slow-wave sleep at the prostaglandin D2-sensitive sleep-promoting zone in the rat brain. Terao, A., Matsumura, H., Saito, M. J. Neurosci. (1998) [Pubmed]
  16. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Jacoby, R.F., Seibert, K., Cole, C.E., Kelloff, G., Lubet, R.A. Cancer Res. (2000) [Pubmed]
  17. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Jacoby, R.F., Marshall, D.J., Newton, M.A., Novakovic, K., Tutsch, K., Cole, C.E., Lubet, R.A., Kelloff, G.J., Verma, A., Moser, A.R., Dove, W.F. Cancer Res. (1996) [Pubmed]
  18. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mohammed, S.I., Bennett, P.F., Craig, B.A., Glickman, N.W., Mutsaers, A.J., Snyder, P.W., Widmer, W.R., DeGortari, A.E., Bonney, P.L., Knapp, D.W. Cancer Res. (2002) [Pubmed]
  19. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Rose, D.P., Connolly, J.M. Cancer Res. (1990) [Pubmed]
  20. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G. Cancer Res. (1990) [Pubmed]
  21. NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2. Liu, G., Ma, W.Y., Bode, A.M., Zhang, Y., Dong, Z. J. Biol. Chem. (2003) [Pubmed]
  22. Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects. Hobbs, D.C. Am. J. Med. (1986) [Pubmed]
  23. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Jacoby, R.F., Cole, C.E., Tutsch, K., Newton, M.A., Kelloff, G., Hawk, E.T., Lubet, R.A. Cancer Res. (2000) [Pubmed]
  24. Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus. Carlton, P.S., Gopalakrishnan, R., Gupta, A., Liston, B.W., Habib, S., Morse, M.A., Stoner, G.D. Cancer Res. (2002) [Pubmed]
  25. Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. García-Vicuña, R., Díaz-González, F., González-Alvaro, I., del Pozo, M.A., Mollinedo, F., Cabañas, C., González-Amaro, R., Sánchez-Madrid, F. Arthritis Rheum. (1997) [Pubmed]
  26. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Rao, C.V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G., Reddy, B.S. Cancer Res. (1991) [Pubmed]
  27. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Savage, R.L., Moller, P.W., Ballantyne, C.L., Wells, J.E. Arthritis Rheum. (1993) [Pubmed]
  28. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. Hsu, A.L., Ching, T.T., Wang, D.S., Song, X., Rangnekar, V.M., Chen, C.S. J. Biol. Chem. (2000) [Pubmed]
  29. Rheumatoid arthritis treated with tenidap and piroxicam. Clinical associations with cytokine modulation by tenidap. Littman, B.H., Drury, C.E., Zimmerer, R.O., Stack, C.B., Law, C.G. Arthritis Rheum. (1995) [Pubmed]
  30. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. Meade, E.A., Smith, W.L., DeWitt, D.L. J. Biol. Chem. (1993) [Pubmed]
  31. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Piazza, G.A., Alberts, D.S., Hixson, L.J., Paranka, N.S., Li, H., Finn, T., Bogert, C., Guillen, J.M., Brendel, K., Gross, P.H., Sperl, G., Ritchie, J., Burt, R.W., Ellsworth, L., Ahnen, D.J., Pamukcu, R. Cancer Res. (1997) [Pubmed]
  32. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Blackburn, W.D., Prupas, H.M., Silverfield, J.C., Poiley, J.E., Caldwell, J.R., Collins, R.L., Miller, M.J., Sikes, D.H., Kaplan, H., Fleischmann, R. Arthritis Rheum. (1995) [Pubmed]
  33. Analgesic efficacy of piroxicam in postoperative dental pain. Desjardins, P.J. Am. J. Med. (1988) [Pubmed]
  34. A long-term evaluation of the treatment of osteoarthritis. Zizic, T.M., Sutton, J.D., Stevens, M.B. Am. J. Med. (1986) [Pubmed]
  35. Piroxicam in recent epidemiologic studies. Bortnichak, E.A., Sachs, R.M. Am. J. Med. (1986) [Pubmed]
WikiGenes - Universities